Conversion of 2-beta-D-ribofuranosylselenazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties.
D000818:Animals; D008401:Gas Chromatography-Mass Spectrometry; D007168:IMP Dehydrogenase / Q000037:antagonists & inhibitors*; D007658:Ketone Oxidoreductases / Q000037:antagonists & inhibitors*; D007941:Leukemia P388 / Q000188:drug therapy*; D007942:Leukemia, Experimental / Q000188:drug therapy*; D051379:Mice; D009243:NAD / Q000031:analogs & derivatives*; D016566:Organoselenium Compounds; D012254:Ribavirin / Q000031:analogs & derivatives / Q000633:toxicity; D012263:Ribonucleosides / Q000138:chemical synthesis / Q000633:toxicity*; D012643:Selenium / Q000138:chemical synthesis / Q000633:toxicity*
D016566:Organoselenium Compounds; D012263:Ribonucleosides; D009243:NAD; D012254:Ribavirin; D007168:IMP Dehydrogenase; D007658:Ketone Oxidoreductases; D012643:Selenium; C039064:selenazofurin; C033706:tiazofurin